BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16971643)

  • 1. Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime.
    Shames R; Satti F; Vellozzi EM; Smith MA
    J Clin Microbiol; 2006 Nov; 44(11):4227-8. PubMed ID: 16971643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
    Burgess DS; Hall RG
    Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.
    Kussmann M; Schuster L; Wrenger S; Pichler P; Reznicek G; Burgmann H; Poeppl W; Zeitlinger M; Wiesholzer M
    Perit Dial Int; 2016 11-12; 36(6):662-668. PubMed ID: 27680756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
    Brown-Elliott BA; Killingley J; Vasireddy S; Bridge L; Wallace RJ
    J Clin Microbiol; 2016 Jun; 54(6):1586-1592. PubMed ID: 27053677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
    Lemaire S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
    J Antimicrob Chemother; 2005 Jun; 55(6):897-904. PubMed ID: 15860552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity and the inoculum effect of ertapenem against Enterobacteriaceae resistant to extended-spectrum cephalosporins.
    Betriu C; Salso S; Sánchez A; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
    Int J Antimicrob Agents; 2006 Jul; 28(1):1-5. PubMed ID: 16769202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
    Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
    J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
    Billal DS; Hotomi M; Yamanaka N
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3463-4. PubMed ID: 17606681
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
    Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
    J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.
    Smith MA; Alperstein P; France K; Vellozzi EM; Isenberg HD
    J Clin Microbiol; 1996 Apr; 34(4):1024-6. PubMed ID: 8815076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.
    Livermore DM; Carter MW; Bagel S; Wiedemann B; Baquero F; Loza E; Endtz HP; van Den Braak N; Fernandes CJ; Fernandes L; Frimodt-Moller N; Rasmussen LS; Giamarellou H; Giamarellos-Bourboulis E; Jarlier V; Nguyen J; Nord CE; Struelens MJ; Nonhoff C; Turnidge J; Bell J; Zbinden R; Pfister S; Mixson L; Shungu DL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1860-7. PubMed ID: 11353638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates.
    Giakkoupi P; Tzouvelekis LS; Daikos GL; Miriagou V; Petrikkos G; Legakis NJ; Vatopoulos AC
    J Clin Microbiol; 2005 Jan; 43(1):494-6. PubMed ID: 15635025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
    Behera B; Mathur P; Das A; Kapil A
    Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.